NCT02975700 2026-01-13
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Daiichi Sankyo
Phase NA Completed
Clinical Trials
12 trialsNCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT04526704 2024-12-30
PLX3397
Daiichi Sankyo
Phase 4 Completed
NCT02371369 2022-05-11
ENLIVEN
Daiichi Sankyo
Phase 3 Completed
NCT02734433 2022-04-25
Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01004861 2022-01-04
Safety Study of PLX108-01 in Patients With Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT04223635 2021-06-22
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
Daiichi Sankyo
Phase EARLY_PHASE1 Completed
NCT03291288 2021-05-14
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Daiichi Sankyo
Phase 1 Completed
NCT01596751 2020-07-17
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT01217229 2020-06-30
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Daiichi Sankyo
Phase 2 Completed
NCT01790503 2020-06-30
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
Phase 1/2 Completed
NCT01349049 2020-03-02
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1/2 Completed